Multiple Myeloma

The approach to treating patients with multiple myeloma will change for physicians, pharmaceutical companies, and even patients themselves.

Data from the AQUILA trial support early intervention with fixed-duration subcutaneous daratumumab for those with high-risk smoldering multiple myeloma.

An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.

The safety profile of carfilzomib, lenalidomide, and dexamethasone was tolerable in fit patients with newly diagnosed multiple myeloma.

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.

Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.

Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as in solid tumors and beyond, includes immune therapies.

Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.

Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.

Shebli Atrash, MD, stated that MRD should be considered carefully as an end point given potential recurrence despite MRD negativity.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.

Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.

SAR446523 is currently being evaluated in a first-in-human phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.

Data from the DREAMM 7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.